APHA Stock: Down 55% From Record High, Is Aphria a Buy Right Now?

Aphria’s recent pullback provides investors an opportunity to buy a quality growth stock at a lower multiple.

Stocks in the cannabis space continue to remain volatile in 2021. Canadian pot stocks were trading near record highs when the country legalized marijuana for recreational use back in October 2018. However, investor enthusiasm soon turned bearish as companies were impacted by a slew of structural issues, including lower-than-expected demand, mounting losses, a thriving black market, and high inventory levels.

The sell-off was further exacerbated amid the COVID-19 pandemic, as retail stores were closed, driving consumer spending significantly lower. In November 2020, several pot stocks gained momentum after Joe Biden won the presidential race south of the border, and investors were optimistic about marijuana legalization at the federal level in the U.S.

Shares of Aphria (TSX:APHA)(NASDAQ:APHA) were trading at $0.75 shortly after it went public in December 2014. It soared to $23 by January 2018 and then fell to a multi-year low of $3.15 last March. Aphria stock then touched a record high of $40.93 in February 2021 and has since lost 55% in market value to trade at its current price of $18.55.

Despite high volatility in stock prices, Aphria has returned over 2,000% in cumulative gains since its IPO. Let’s see if the recent pullback presents a buying opportunity for investors.

Aphria’s recent quarterly results were disappointing

In the fiscal third quarter of 2021, Aphria reported net sales of $153.6 million. This reflected a year-over-year increase of 6.4% compared to net sales of $144.4 million in the prior-year period. Comparatively, Bay Street expected Aphria to post sales of $166.2 million in the December quarter.

The company also reported an adjusted net loss of $47.9 million, or $0.15 per share, marking a significant deterioration compared to an adjusted net loss of $9.8 million, or $0.04 per share, in fiscal Q3 of 2020. Analysts forecast Aphria’s net loss at $0.04 in Q3 of fiscal 2021.

Aphria generates sales from distribution revenue derived from the company’s CC Pharma operations in Germany. It also sells recreational and medical marijuana products.

The company’s net cannabis sales fell 24% on a sequential basis to $51.7 million while distribution revenue fell 5% to $87.1 million in Q3. These declines were attributed to lockdowns in Canada and Germany as well as lower marijuana selling prices.

What’s next for investors?

While Aphria sales in Q3 were less than impressive, the company retained its pole position in Ontario and Alberta in terms of cannabis sales. It is also the second-largest pot seller in Quebec. Aphria managed to record $14.8 million in net sales from its alcoholic beverage business, and the company’s acquisition of craft beer maker Sweetwater Brewing will hold it in good stead in the long term to help it gain traction in this disruptive vertical.

Aphria has posted eight consecutive quarters of positive adjusted EBITDA, and in Q3 this figure rose to $12.7 million, which was similar to its prior-year period.

The most important driver of Aphria stock is its upcoming merger with Tilray, which will make the combined entity the largest cannabis company in the world. Both the companies already have a presence in the U.S. and can scale production once marijuana is legalized in the country. Aphria’s strong balance sheet and its ability to consistently post a positive EBITDA make it a top pick given the recent pullback.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Medicinal research is conducted on cannabis.
Cannabis Stocks

Top Canadian Stocks to Buy Right Now With $1,000

Cannara, Source Energy and CareRx just updated investors. See what $1,000 can buy in these Canadian stocks, plus the risks…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Stocks for Beginners

This Cannabis Stock Jumped 12% in a Day: The Math Says Be Careful

Tilray's record revenue came with declining cannabis sales and negative free cash flow, making the investment much more speculative than…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf’s Takeover Bid for Aurora Cannabis: What Investors Need to Know

Curaleaf's takeover bid for Aurora Cannabis offers a premium but brings stock, debt, and deal risks. Here’s what ACB investors…

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Curaleaf Just Announced a Hostile Takeover Bid for Aurora Cannabis. Here’s What This Means for Investors.

It's appealing directly to the Canadian company's shareholders with a cash-and-stock offer.

Read more »

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »